You may recall a little over a year ago Endo Pharmaceuticals (NASDAQ: ENDP) acquired RxKinetix whose lead product was RK-0202, a topical oral-rinse with the active ingredient formulated in its proprietary ProGelz® drug delivery platform and was in Phase II. It sounds as if great progress is being made on RK-0202 which subsequently has become [...]